You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

27 search results for: disease background

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

Chronic Spontaneous Urticaria: <b>Disease</b> Overview

interactivity

Chronic Spontaneous Urticaria: Disease Overview

5 min

Dermatology

Explore CSU: Uncover its clinical features, epidemiology, and its profound impact on patients’ lives in this interactive tool.

Chronic Spontaneous Urticaria (CSU): <b>Disease</b> Overview

Infographic

Chronic Spontaneous Urticaria (CSU): Disease Overview

5 min

Dermatology

Explore CSU: Uncover its clinical features, epidemiology, and its profound impact on patients' lives in this interactive tool.

Type 2 Inflammation and Its Role in Associated Dermatologic <b>Disease</b>s: A Two-Part Series

expert video

Type 2 Inflammation and Its Role in Associated Dermatologic Diseases: A Two-Part Series

30 min

Type 2 Inflammation

Join Dr. Raj Chovatiya as he reviews the pathophysiology and the role of type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

<b>Disease</b>-Specific Aspects of Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Presentation and Diagnosis of AD and PN

14 min

Dermatology

Presentation of atopic dermatitis and prurigo nodularis, and the impact of PN as an intensely pruritic disease – Clip from the ADVENT symposium at AAD 2023.

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

expert video

Type 2 Inflammation and Chronic Pruritus in AD and PN

7 min

Dermatology

Highlights from the ADVENT symposium at AAD 2023 on the shared and unique roles of type 2 inflammation in atopic dermatitis and prurigo nodularis.

expert video

Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation

23 min

Dermatology

Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.

expert video

Type 2 Inflammation Contributes to the Signs and Symptoms of AD and PN

6 min

Dermatology

The impact of type 2 inflammation, neuroimmune axis dysfunction, and skin tissue on the signs and symptoms of atopic dermatitis and prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region